Tehran University of Medical Sciences Unveils 60 New Pharmaceutical Products
Addressing the ceremony, Seyed Hamid Khoyee, the head of the Incubator Center for the Development of Pharmaceutical Products affiliated to Tehran University of Medical Sciences, said that most of these drugs are available in the market and were presented to the patients.
“The Incubator Center for the Development of Pharmaceutical Products has produced 120 important pharmaceutical products exclusively since its establishment 20 years ago,” he added, noting that the first high-tech medicine in the country were produced by this center, among which are Factor VIII drugs and blood products.
Khoyee noted that the Center produces 11 drugs exclusively, saying, “$671 million worth of pharmaceutical products were exported by this Center last year.”
During the ceremony, the brain angiography department of Shariati Hospital was also inaugurated and the second angiography machine of Baharloo Hospital's heart center started operation.
Iran has gained self-sufficiency in production of different types of drugs and medical equipment in recent years.
In a relevant development, an Iranian knowledge-based company succeeded in production of a three-month slow-release drug for the treatment of precocious puberty and some types of breast cancer, breaking the US monopoly.
A knowledge-based company in Iran will soon present its three-month slow-release drug ‘Triptorelin Pamoate’ to the country's pharmaceutical market. This medicinal product is used in the treatment of prostate cancer, precocious puberty in children, uterine diseases and some types of breast cancer.
“The production technology of this product is based on in situ-forming gels (formed at the injection spot), which has been indigenized in the country after years of academic research,” said Mohammad Taqi Fat'hi, the managing-director of the knowledge-based company.
He added that the injectable systems formed on the spot consist of two separate syringes, one containing the active pharmaceutical ingredient and the other containing a biocompatible and biodegradable polymer carrier (absorbable by the body).
“When using this drug, two syringes are connected to each other before injection, and the drug and the carrier are well mixed with the reciprocating movements of the syringes’ plunger,” Fat'hi said, adding that by injecting this liquid system into the body, the system becomes a semi-solid depot in the vicinity of interstitial water and traps the drug inside.
“This semi-solid capsule slowly provides the medicine needed by the patient in consecutive days and removes the need for frequent daily injections of medicine,” he explained.
4155/v
